Category Archives: News
FECAL CALPROTECTIN TESTING: AN INVESTIGATION OF PATIENT COMPLIANCE AND PERCEPTIONS
Inflammatory Bowel Disease (IBD) is a lifelong illness requiring close management. Prompt disease recognition and tight control of disease activity reduces disease morbidity and improves outcomes1. Endoscopy with histologic examination is the gold stan… Continue reading
SIMPLE SUGAR TRIGGERS SPONTANEOUS COLITIS DEVELOPMENT IN IL10-/- MICE
The Western diet characterized by high fat and high sugar is considered a risk factor for inflammatory bowel disease (IBD) such as colitis. However, the precise role of sugar in colitis pathogenesis is poorly understood. We, therefore, investigated the… Continue reading
DECONSTRUCTING DISTRESS: STAKEHOLDER ENGAGEMENT FOR EVIDENCE-BASED, PATIENT-CENTERED INTERVENTIONS FOR THE MANAGEMENT OF IBD-ASSOCIATED PSYCHOLOGICAL DISTRESS
The growing prevalence of Inflammatory Bowel Disease (IBD) along with increasing complexity of providing high-quality, patient-centered care within a resource-constrained healthcare environment presents a major challenge. IBD-related psychological dist… Continue reading
REAL-WORLD VEDOLIZUMAB PHARMACOKINETIC STUDY IN CHILDREN IDENTIFIES TWO NOVEL BIOMARKERS OF DRUG CLEARANCE
Use of vedolizumab in pediatric inflammatory bowel disease (IBD) often requires an interval intensification from standard dosing due to distinct pharmacokinetics (PK) in children. Adult population PK models found inclusion of albumin, weight, anti-TNF … Continue reading
A QUALITATIVE STUDY EXPLORING MEANINGFUL IMPROVEMENT IN BOWEL URGENCY AMONG ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Ulcerative Colitis (UC) is a chronic disease with periods of relapse and remission. Bowel urgency, the sudden or immediate need for a bowel movement, is one of the most bothersome symptoms experienced by patients with UC. This study explored how patien… Continue reading
EFFICACY OF LOW DOSE NALTREXONE IN PATIENTS WITH CROHN’S COLITIS AND ILEITIS
In a Phase 2 placebo-controlled trial, low dose naltrexone (LDN) improved inflammation of the gastrointestinal mucosa and improved clinical activity scores in patients with mild to moderate Crohn’s disease (CD). We present two patients with symptomatic… Continue reading
CELL-AUTONOMOUS HEDGEHOG SIGNALING CONTROLS TH17 DIFFERENTIATION TO DRIVE INTESTINAL INFLAMMATION AND IS A DRUGGABLE TARGET FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
T helper 17 (Th17) cells play a key role in barrier protection in the gastrointestinal tract but are also key pathological drivers of Inflammatory Bowel Disease (IBD). Although a number of key transcription factors governing Th17 differentiation have b… Continue reading
CORRELATION OF FECAL, PLASMA, SERUM, AND SALIVARY CALPROTECTIN TO ENDOSCOPIC AND HISTOLOGIC OUTCOMES IN PATIENTS WITH CROHN’S DISEASE
Monitoring disease activity in Crohn’s disease is important as achieving endoscopic remission significantly improves clinical outcomes. Fecal calprotectin is a common non-invasive biomarker for monitoring disease activity. However, fecal calprotectin d… Continue reading
PREDICTIVE PERFORMANCE OF DIFFERENT POPULATION PHARMACOKINETIC MODELS IN A REAL-WORLD COHORT OF CROHN’S DISEASE PATIENTS
We have previously published the results of an infliximab (IFX) population PK model in children and young adults with Crohn’s disease (CD). We found that prediction accuracy was improved with less unexplained variability when the five covariates of dru… Continue reading
SUCCESSFUL CLEARANCE OF CYTOMEGALOVIRUS COLITIS IN ACUTE SEVERE ULCERATIVE COLITIS DURING INDUCTION OF OZANIMOD
Cytomegalovirus (CMV) colitis, commonly observed in patients with acute severe ulcerative colitis (UC), increases the risk for colectomy and treatment resistance. Unfortunately, corticosteroids and immunomodulators increase CMV reactivation and infecti… Continue reading